-
11.19.2021 | Partnering to Protect: Public & private sectors unite against antimicrobial resistance
A webinar convening international experts allowed us to explore the barriers to building a robust pipeline of next generation AMR innovation. The key message: AMR is a global challenge, and we must work together as an international community to spur innovation, support whole-of-ecosystem changes, and learn from one another's different approaches.
-
10.12.2021 | CARB-X 2020-21 annual report: CARB-X surpasses all goals in first five years in combatting antibiotic resistant-bacteria
CARB-X closed its fifth fiscal year on July 31, 2021 with US$361 million awarded to 92 projects funding since inception. In its latest fiscal year, CARB-X invested in 25 new projects across all three pillars – preventatives, diagnostics, and therapeutics. This year saw two more successful graduations from the portfolio, four more First-in Human programs launch, and several strategic augmentations of the portfolio including in the areas of: gonorrhea, bacteriophage, vaccines, peptides and polymyxins, and anti-virulence factors.
-
07.29.2021 | CARB-X celebrates five years of progress in early-stage product development against antibiotic-resistant bacteria
CARB-X, a global non-profit partnership led by Boston University, is celebrating five years of progress in funding and supporting the development of innovative products targeting antibiotic-resistant bacteria. Since it was founded in July 2016, CARB-X has invested $361 million in non-dilutive funding to develop innovative therapeutics including new classes of antibiotics and non-traditional agents, vaccines and other preventatives such as CRISPR-phage, microbiome-modifying agents and antibodies, and rapid diagnostics.
-
06.08.2021 | CARB-X is funding Accelerate Diagnostics to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections
CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds.
-
06.01.2021 | CARB-X is funding Swiss pharma company BioVersys to develop a new class of antibiotics to treat infections caused by multidrug-resistant ESKAPE pathogens
CARB-X is awarding BioVersys, a pharmaceutical company headquartered in Basel, Switzerland, up to US$4.35 million in non-dilutive funding, to develop a new class of antibiotics to treat life-threatening infections caused by ESKAPE pathogens, bacteria that have developed resistance to most antibiotics available today. BioVersys could receive up to $10.98 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds.
-
05.27.2021 | CARB-X is funding SNIPR BIOME to develop a CRISPR-engineered drug to eradicate Escherichia coli (E. coli) bacteria in cancer patients to prevent deadly infections
CARB-X is awarding SNIPR BIOME ApS, a CRISPR- and microbiome-biotechnology company in Copenhagen, Denmark, up to US $3.9 million to develop an innovative new drug to prevent E. coli infections in cancer patients, which can be life-threatening. Under the award, SNIPR BIOME may be eligible for up to $6.3 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds.
-
05.19.2021 | CARB-X is funding Basilea Pharmaceutica to develop a new class of antibiotics to treat drug-resistant Gram-negative bacteria
CARB-X is awarding Basilea Pharmaceutica International (SIX: BSLN), Basel, Switzerland, up to US $2.7 million to develop a novel class of antibiotics to treat Gram-negative bacterial infections. Gram-negative bacteria, often called ‘superbugs’ because they have developed resistance at an alarming pace to existing antibiotics, kill an estimated 700,000 people each year around the world.
-
05.18.2021 | CARB-X is funding Summit Therapeutics to develop a new antibiotic to treat multidrug-resistant infections caused by carbapenem-resistant Enterobacteriaceae (CRE)
CARB-X is awarding Summit Therapeutics, (NASDAQ: SMMT) headquartered in Cambridge, MA, USA, with its Discuva subsidiary located in Cambridgeshire, UK, up to US$4.1 million in non-dilutive funding to develop a first-in-class antibiotic to treat multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections including those caused by serious human pathogens such as Escherichia coli and Klebsiella pneumoniae. Under the award, Summit could receive additional funding of up to $3.7 million from CARB-X if project milestones are achieved, subject to available funds. The award will help the company progress the SMT-738 antibiotic project through preclinical and Phase 1a clinical development.
-
05.10.2021 | CARB-X is funding Australian-biotech SpeeDx to develop a rapid point-of-care diagnostic for sexually transmitted diseases Chlamydia trachomatis and Neisseria gonorrhoeae
CARB-X is awarding SpeeDx, a diagnostics company in Sydney, Australia, up to $1.8 million to develop a rapid test for Chlamydia trachomatis and Neisseria gonorrhoeae, sexually transmitted bacteria that can cause serious infections and that are spreading around the world at alarming rates. SpeeDx is also eligible for $1.9 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds.
-
04.27.2021 | CARB-X is funding UK-biotech GenomeKey to develop a rapid diagnostic for sepsis, a leading cause of death in hospitals
CARB-X is awarding GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $3.0 million in non-dilutive funding to develop an innovative rapid diagnostic for sepsis. GenomeKey is eligible for up to $6.5 million in additional awards if the project achieves certain milestones, subject to available funds.
-
04.20.2021 | CARB-X is funding Baebies Inc. to develop a rapid diagnostic for neonatal sepsis
CARB-X is awarding Baebies Inc., based in Durham, North Carolina, USA, up to $3.9 million to develop a rapid easy-to-use diagnostic for neonatal sepsis, a severe condition related to bacterial infections which, according to studies, kills an estimated 1.4 million young children world-wide each year.
-
04.19.2021 | CARB-X is funding Phico Therapeutics to develop an engineered bacteriophage drug to treat ventilator-associated pneumonia caused by drug-resistant Pseudomonas aeruginosa
CARB-X is funding Phico Therapeutics, in Cambridge, UK, to develop a new intravenous engineered bacteriophage drug to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa, a serious problem in hospitals, intensive-care units and health-care settings.
-
04.06.2021 | CARB-X is funding Novel Microdevices to develop a rapid and portable diagnostic for sexually transmitted diseases including antibiotic-resistant infections
CARB-X is awarding Novel Microdevices, Inc. of Baltimore, Maryland, USA, up to $3.6 million in non-dilutive funding, and, subject to available funding, up to an additional $10.2 million if certain project milestones are met, to develop a new rapid molecular test to diagnose sexually-transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae.
-
03.30.2021 | CARB-X is funding University of Oxford’s Jenner Institute to develop a new vaccine to prevent gonorrhea
CARB-X is awarding up to US$2 million to the Jenner Institute, part of the University of Oxford, UK, to develop a novel vaccine to prevent gonorrhea, a common sexually-transmitted bacterial infection that has developed resistance to most antibiotics. Under the award, the Institute would be eligible for up to $5.3 million more if the project progresses through certain project milestones, subject to available funding.
-
03.22.2021 | World’s leading funders of antibacterial research provide guidance on stewardship and access in the fight against antibiotic-resistant bacteria
Leading funders of research and development of new antibiotics and other products targeting antibiotic-resistant bacteria have just released a document providing comprehensive guidance on strategies and activities to support Stewardship and Access for companies bringing new antibacterial products to market. The Stewardship and Access Plan Development Guide provides companies with a framework to develop plans so that their product will be used responsibly, minimizing the spread of antibiotic-resistant bacteria while helping patients get access to life-saving products.
-
03.09.2021 | CARB-X is funding Affinivax to develop a novel vaccine to prevent Staphylococcus aureus bacterial infections
CARB-X is funding Affinivax, a Cambridge, Massachusetts, USA, biotech, to develop a new vaccine that will prevent Staphylococcus aureus bacterial infections, healthcare-associated infections that are a major health threat particularly to high-risk and older patients.
-
03.01.2021 | CARB-X is funding GSK to support the development of two unique vaccine projects that aim to prevent serious bacterial infections killing thousands worldwide each year
CARB-X is funding the GSK Biologicals and its affiliate GSK Vaccines Institute for Global Health (GVGH), based in Siena, Italy, to develop new vaccines to prevent serious infections caused by two different pathogens. Together, the two awards could be worth potentially more than $18 million if project milestones are met, subject to available funding.
-
02.22.2021 | CARB-X is funding The University of Queensland to develop a new drug targeted to low- and middle-income countries that would breathe new life into existing readily-available antibiotics in the fight against drug-resistance
CARB-X is awarding up to US$2.2 million to The University of Queensland’s (UQ) Institute for Molecular Bioscience (IMB) to expand its Octapeptin research program to develop a new drug designed for use in low- and middle-income countries (LMICs) where there are high levels of drug-resistant bacteria.
-
02.03.2021 | CARB-X is funding French biotech Mutabilis to develop a new class of antibacterials to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria
CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria.
-
02.01.2021 | CARB-X is funding the development of Avails Medical’s rapid antibiotic susceptibility testing technology to identify the most effective antibiotic therapy for serious blood infections
CARB-X is funding Avails Medical, a Menlo Park, CA, USA, diagnostics company, to develop an electronic antibiotic susceptibility testing (AST) device to speed up health care providers’ ability to determine the most effective antibiotic treatment for serious and life-threatening blood infections.
-
01.27.2021 | CARB-X is funding Seattle-based Lumen Bioscience to develop a new oral monoclonal antibody cocktail to prevent serious diarrheal diseases
CARB-X is awarding up to US$5.35 million to Lumen Bioscience, in Seattle, WA, USA, to develop a new immunotherapy to prevent diarrheal diseases caused by two deadly pathogens, Campylobacter jejuni and enterotoxigenic E. coli.
Toggle navigation